Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Rheumatoid arthritis (RA) is one of more than 100 types of arthritis. This chronic autoimmune
disorder affects the lining of synovial joints in about 0.5% of people and may induce severe …

Because genetic alterations including mutations, overexpression, translocations, and
dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this …

Inhibition of cyclin-dependent kinases (CDKs) has become an effective therapeutic strategy
for treating various diseases, especially cancer. Over almost three decades, although great …

Owing to genetic alterations and overexpression, the dysregulation of protein kinases plays
a significant role in the pathogenesis of many autoimmune and neoplastic disorders and …

More than 10 disease-modifying therapies (DMT) are approved by the European Medicines
Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple …

The discovery of the phosphatidylinositol 3-kinase (PI 3-kinase) pathway was a major
advance in understanding eukaryotic signal transduction. The high frequency of PI 3-kinase …